Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

25.97 1.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.38

Massimo

26.29

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+28.09% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

593M

2.6B

Apertura precedente

24.01

Chiusura precedente

25.97

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 ago 2026, 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

13 ago 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

13 ago 2026, 23:51 UTC

News

Milestone Scientific reported second-quarter sales of $2.841 million, exceeding estimates. Shares are higher in after-market hours following the earnings announcement.

13 ago 2026, 23:51 UTC

News
Social Media

Campbell Soup Co filed for a mixed securities shelf to raise capital. Shares are higher in after-market trading amid positive social media sentiment.

13 ago 2026, 23:51 UTC

News
Social Media

Charter Communications received final approval for its Cox acquisition, but shares are trading lower in after-market hours, reflecting downward pressure since Thursday's close.

13 ago 2026, 23:46 UTC

News

Citi analyst Ronald Josey raised Wayfair's price target to $133.00 from $95.00, maintaining a Buy rating. Shares are trading higher in after-market hours.

13 ago 2026, 23:46 UTC

News
Correlated Moves

Synchrony Financial shares declined in after-market hours following the appointment of Nimrod Barak as Chief AI Officer, effective June 30, 2026.

13 ago 2026, 23:46 UTC

News

UWM Holdings Corp secures $2.05 billion investment from Oaktree and SFS Group. Shares are trading higher in after-market hours following the announcement.

13 ago 2026, 23:41 UTC

News

EPR Properties declared a monthly cash dividend of $0.31 per share, payable September 15, 2026, as shares moved higher during after-market hours.

13 ago 2026, 23:41 UTC

News

Credicorp Ltd reported second-quarter earnings of $7.29 per share, exceeding estimates. The stock moved higher during after-market hours following this performance.

13 ago 2026, 23:41 UTC

Social Media
News

Eton Pharmaceuticals reported record revenue of $37.6 million and raised its full-year guidance to over $145 million, driving shares higher in after-market trading.

13 ago 2026, 23:41 UTC

News

Norway's sovereign wealth fund increased its Bitcoin exposure through MicroStrategy investments. Bitcoin is trading lower today, remaining below its 20-day moving average.

13 ago 2026, 23:36 UTC

News

Lucid Group Inc introduced the Lucid Gravity GT-S SUV priced at $125,900, but shares declined in after-market trading following the announcement.

13 ago 2026, 23:31 UTC

News

Western Union shares rise in after-market trading following New York Governor Kathy Hochul's approval of its acquisition of International Money Express.

13 ago 2026, 23:31 UTC

Correlated Moves
News
Social Media

Microsoft shares are trading lower after a report on OpenAI's $40 billion revenue run rate and Iren's $9.7 billion cloud services contract.

13 ago 2026, 23:31 UTC

Social Media
News

Micron Technology launches a $250 million AI-focused fund, raising total commitments to $550 million. Shares are trading higher in after-market hours.

13 ago 2026, 23:31 UTC

News
Social Media

Nu Holdings Ltd shares rose in after-market trading following strong Q2 results, with revenue of $5.9 billion surpassing estimates and net profit reaching $1.06 billion.

13 ago 2026, 23:26 UTC

News

CoreCivic Inc shares rose in after-market trading following positive analyst ratings updates and a raised price target from Benchmark Co. to $45.00.

13 ago 2026, 23:26 UTC

Correlated Moves
News

Diodes Inc announced a $325 million private placement of convertible senior notes due 2031. Shares are lower in after-market trading amid broader market trends.

13 ago 2026, 23:26 UTC

News

Hewlett Packard Enterprise shares rose in after-market trading, buoyed by positive sentiment from Cisco's earnings and broader market gains.

13 ago 2026, 23:21 UTC

News

Knight-Swift Transportation affirms quarterly cash dividend of $0.20 per share, though shares are trading lower in after-market hours.

13 ago 2026, 23:21 UTC

News

Rapid7 Inc shares rose in after-market trading after reporting adjusted EPS of $0.44, exceeding expectations, and raising full-year guidance to $1.81.

13 ago 2026, 23:16 UTC

News
Correlated Moves

Citigroup's U.S. Consumer Cards business will acquire Kard Financial to enhance credit card rewards for its 70 million cardmembers. Shares are little changed in after-market trading.

13 ago 2026, 23:16 UTC

Correlated Moves
News

Sunrun Inc. shares declined in after-market trading, reflecting broader market trends. Recent financial results showed sales of $543.73 million and revenue of $869.99 million.

13 ago 2026, 23:16 UTC

News

Jack in the Box Inc shares rose in after-market trading following UBS and Citigroup raising their price targets to $20, indicating a stable outlook.

13 ago 2026, 23:11 UTC

News

Sabre Corp reported second-quarter revenue of $712 million and raised its full-year profitability outlook, though shares are trading lower in after-market hours.

13 ago 2026, 23:06 UTC

Social Media
News

Tesla shares gained in after-market hours following the end of a lengthy strike by IF Metall and as Michael Burry covered his short position.

13 ago 2026, 23:06 UTC

News

Silicon Motion Technology closed a $1.15 billion offering of Convertible Senior Notes due 2031, with shares trading higher in after-market hours.

13 ago 2026, 23:06 UTC

News
Event

Target Corp will announce Q2 FY2026 earnings on August 19, with an estimated EPS of $2.24 and revenue of $25.7 billion. Shares showed little change after hours.

13 ago 2026, 23:02 UTC

Social Media
News

Cboe Global Markets announced a dividend increase to $0.86 per share, effective September 15, 2026. Shares are trading higher in after-market hours.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

28.09% in crescita

Previsioni per 12 mesi

Media 32.65 USD  28.09%

Alto 45 USD

Basso 21.6 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat